But you don't mention the $470 million in cash. When Cash is greater than debt the debt is not a problem. I am sorry you are watching you life saving evaporate as the stock goes up and your short is costing you more every day. Maybe you should just cover before your debt gets out of hand.
how can it be overvalued when compared to Medivation? Isn't the whole concept of a company to use employees, assets, debts to turn a biotech company from a venture business to a eventually significantly money making business producing a valuable service/product to the world.
Exelixis management already announced Exelixis had sufficient cash to bring its trials to fruition. MTC revenue is only the tip of the ice berg of greater revenues to follow. If the prostrate cancer results continue with Cabo, Exelixis valuation will exceed Medivation and more.
Seriously? You want to talk about convertible debt obligations due in 2019? ....7 years out? Seriously? On this company? I don't see this as a concern at all! Drop in the bucket to where I see EXEL by then!
Why doesn't any of the pom-pom waving perma-bulls even mention this fact on the message board? They only scream about the cash the company has. It's almost as if they are turning a "blind eye" to the debt! Nahhhh, they wouldn't do that ;-)